[Form 4] Agenus Inc. Insider Trading Activity

Rhea-AI Filing Summary

Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Timothy Wright received a total of 15,750 stock options on 06/17/2025 under the company’s 2019 Amended & Restated Equity Incentive Plan.

The options carry an exercise price of $3.02 and expire on 05/28/2035. Two tranches were awarded: 750 options that vest one-third on 05/28/2026 and quarterly thereafter, and 15,000 options that vest fully one year after the grant date. All awards were reported as directly held; no shares were sold or otherwise disposed. The filing is a routine disclosure of director compensation rather than a change in ownership of common stock.

Insights

Corporate Governance Analyst

Routine director option grant; immaterial for valuation

The Form 4 records an equity award worth roughly $48k (15,750 options × $3.02 strike) to board member Timothy Wright. Multi-year vesting limits short-term dilution and signals standard alignment of director interests with shareholders. No open-market buying or selling occurred, so the filing offers no directional insight into insider sentiment. From a governance lens, the grant complies with the shareholder-approved 2019 plan and does not alter the company’s capital structure in a material way.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wright Timothy

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.02	06/17/2025		A		750		(1)	05/28/2035	Common Stock	750	$0	750	D
Stock Option	$3.02	06/17/2025		A		15,000		(2)	05/28/2035	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026, and the balance vesting in equal quarterly installments thereafter.

2. Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

	/s/Christine Klaskin, as Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did AGEN director Timothy Wright receive on 06/17/2025?

The Form 4 reports a grant of 15,750 stock options to Timothy Wright.

What is the exercise price and expiration date of the newly granted AGEN options?

The options have an exercise price of $3.02 and expire on 05/28/2035.

When do the 15,000 stock options awarded to Timothy Wright fully vest?

The 15,000-option tranche vests in full on the one-year anniversary of the 05/28/2025 grant date.

Did Timothy Wright sell any AGEN shares in this Form 4 filing?

No. The filing only discloses option grants; there were no share sales or disposals.